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untreated controls to 0.6 ml 6 0.1/min in flosulide-treated ratsEffect of flosulide, a selective cyclooxygenase 2 inhibitor, on
with PHN (P , 0.01) after four weeks.passive Heymann nephritis in the rat.
Conclusions. Under the influence of flosulide, a highlyBackground. Nonsteroidal anti-inflammatory drugs (NSAIDs)
COX-2–selective inhibitor, we observed an antiproteinuricinduce an inhibition of cyclooxygenase (COX), an enzyme that
drug effect. The inflammation in PHN induced COX-2 proteinmakes prostaglandins. Two isoforms of COX exist: COX-1 rep-
expression that was not affected by low-dose flosulide. COX-1resents the constitutively expressed enzyme, whereas COX-2
and COX-2 protein expression was affected by high-dose flo-is the inducible isoform. This study investigated the role of
COX-2 in the inflammatory processes of the kidneys of rats sulide, which therefore might lose its selectivity. High-dose
with passive Heymann nephritis (PHN), and focused of the flosulide induced a decrease in glomerular prostanoid produc-
effect of a selective COX-2 inhibitor, flosulide. COX-2–selective tion possibly because of COX-1 inhibition. Our results suggest
inhibitors are thought to represent potent anti-inflammatory that the therapeutic use of flosulide in proteinuria seems advan-
agents without major renal side effects. tageous and deserves further studies because the basal prosta-
Methods. PHN was induced by injecting heterologous Fx1A glandin levels remain unchanged in the low-dose–treated
antiserum into female Wistar rats. Two treatment groups, each group, indicating that the compensatory capacity of prostaglan-
consisting of 12 rats with PHN, received either 3 or 9 mg of din production, which is essential for the regulation of renal
flosulide/kg body wt/day and were compared with untreated hemodynamics, is maintained.
controls. After four weeks, the generation of thromboxane B2
(TxB2) and 6-keto-PGF1a were determined in renal tissue and in
urine. COX-2 protein expression was investigated by Western
Nonsteroidal anti-inflammatory drugs (NSAIDs) be-blotting using a selective antibody.
Results. Rats with PHN exhibited a marked proteinuria of long to the most comprehensively investigated drugs.
71 6 8 mg/24 hr as compared with 2.0 6 0.3 mg/24 hr in healthy Nevertheless, their use is limited by various side effects.
controls (P , 0.01). Treatment with flosulide reduced the pro- NSAIDs act via inhibition of cyclooxygenase (COX) ac-teinuria to 26.1 6 9 mg/24 hr at 3 mg flosulide/kg body wt/day
tivity, thereby blocking prostaglandin production. COXsand 35.5 6 6 mg/24 hr at 9 mg/kg body wt/day, which was
equivalent to a reduction of proteinuria by a maximum of 65% catalyze the conversion of arachidonic acid into prosta-
(P , 0.05). This was accompanied by an increase in glomerular glandin H2 (PGH2), a precursor for the formation of
TxB2 from 3073 6 355 to 5255 6 1041 pg/mg glomerular protein prostacyclin and thromboxane [1]. Two isoforms exist:
and 6-keto-PGF1a from 1702 6 161 to 2724 6 770 pg/mg glo- a constitutive form (COX-1) that occurs ubiquitously inmerular protein in rats with PHN. COX-2 protein expression
the body, appearing in the gastrointestinal tract, plate-was also highly elevated in comparison to healthy controls.
Low-dose flosulide treatment had no effect on COX protein lets, and kidney. COX-1 activity fulfills a housekeeping
expression and renal prostaglandin formation. High-dose flo- function, that is, it maintains the prostaglandin produc-
sulide treatment reduced renal prostaglandin production and tion necessary for physiological functions [2]. The induc-caused a marked decline in COX-1 and COX-2 protein expres-
ible isoform (COX-2) is expressed in inflammatory con-sion. Urine prostanoid excretion remained unchanged in all
ditions and is regulated on the transcriptional level [3, 4].therapeutic groups. There was a small though significant reduc-
tion in renal creatinine clearance from 0.86 ml 6 0.2/min in Most available COX inhibitors act nonselectively [5] in
that they inhibit both COX-1 and COX-2 at anti-inflam-
matory concentrations, especially COX-1 inhibition [6].Key words: cyclooxygenase, proteinuria, kidney, thromboxane A2,
NSAIDs, renal hemodynamics. Therefore, their therapeutic benefit is limited by gastric
and renal toxicity, which in turn appears to be relatedReceived for publication July 21, 1998
to the inhibition of prostaglandin production in theseand in revised form April 22, 1999
Accepted for publication June 7, 1999 tissues [7]. NSAIDs have also been used to treat the
nephrotic syndrome [8]. The decline in proteinuria ob- 1999 by the International Society of Nephrology
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served in the nephrotic syndrome is assumed to occur of the Fx1A antibody. Group A animals received no
treatment but NaCl solution as placebo.at least in part because of a reduction in renal plasma
flow, eventually resulting in a reduction in the glomerular (2) Group B. PHN was induced in 12 female Wistar
rats (230 to 250 g) by intravenous injection of 1.0 ml offiltration rate. The action of NSAIDs on renal plasma
flow is at least partially caused by a suppression of COX anti-Fx1A antibody into the tail vain. Group B animals
received no treatment except for a NaCl solution as theand COX-dependent metabolites. Therefore, therapeu-
tic application of selective COX-2 inhibitors might result placebo.
(3) Groups C and D. Twenty-four PHN rats comprisedin a more selective inhibition of the inflammatory pro-
cesses without influencing basal COX-1–dependent pros- Groups C and D and were subjected to flosulide treat-
ment. To determine the dose-dependent effect of flosulidetaglandin synthesis [9].
The aim of this study was to determine the therapeutic on PHN, 12 rats (group C) were treated with 3 mg flosul-
ide/kg body wt/day and 12 rats (group D) received 9 mgefficacy of 6-(2,4 difluorophenoxy-5-methyl-sulfonyl-
amino-1-indanone (CGP 28,238), a phenoxyindane- flosulide/kg body wt/day. The choice of doses resulted
from recommendations of the Schering AG Berlin basedmethane-sulfonamide-flosulide, in a model of glomerular
nephritis, the passive Heymann nephritis (PHN). A po- on experimental results in animals that were raised by
Schering during development of the drug [13].tent anti-inflammatory effect of flosulide is the previously
established inhibition of granulocyte function [10]. Two Electron microscopic diagnosis of PHN. For morpho-
logical studies, as early as six hours after the inductionquestions were addressed: (a) Does flosulide modify glo-
merulonephritis, that is, the inflammatory process, and of PHN and also at other time points afterwards, several
animals were sacrificed and examined to assure there(b) is this in any way correlated to the inhibition of
prostaglandin function? was onset of PHN. Tissue for light microscopy was fixed
in 4% formaldehyde, and paraffin sections were stained
with periodic acid-Schiff and hematoxylin and eosin
METHODS
stains to evaluate any changes. Electron microscopic
Materials changes were detected as electron dense “humps” local-
ized next to the basal membrane in glomeruli.Flosulide or 6-(2,4 difluorphenoxy-)5-methyl-sulfonyl-
amino-1-indanon was provided by Schering (Berlin, Ger- Schedule of laboratory tests and sample collecting.
Therapeutical treatment with flosulide or application ofmany), Triton X 100 was purchased from Serva (Heidel-
berg, Germany) and ethylenediaminetetraacetic acid placebo started one week after induction of the PHN and
continued for four weeks. In PHN, proteinuria occurred(EDTA) was purchased from Merck (Darmstadt, Ger-
many). All other chemicals were purchased from Sigma immediately post-induction and reached its maximum
level after approximately 14 days.(Deisenhofen, Germany). The anti-Fx1A antibody was
a kind gift from Dr. B. Iversen (Bergen, Norway). Once every week during the study, rats were posi-
tioned in metabolic cages to collect 24-hour urine sam-
Passive Heymann nephritis in rats ples. Urine creatinine and protein levels were measured
using standard laboratory techniques.All rats were clinically investigated and subjected to
standard laboratory tests for four weeks before being Weekly blood samples were taken from the retrobul-
bar plexus of the animals while they were under ethersacrificed for kidney removal.
Induction of passive Heymann nephritis in rats. PHN anesthesia to determine creatinine and protein values in
serum for clearance calculation. Blood samples were alsowas induced in female Wistar rats (230 to 250 g) by
intravenous injection of 1.0 ml of anti-Fx1A antibody collected for determination of thromboxane and prosta-
cyclin in the serum.prepared and characterized as previously described [11].
The Fx1A antigen represents a tubular antigen of the On day 28, animals were sacrificed by carbon monox-
ide poisoning. Kidneys were removed immediately forrat kidney. Anti-Fx1A antibodies were raised in rabbits
by intramuscular injection of several probes of Fx1A isolation of glomeruli.
antigen resolved in “Freud’s incomplete-adjuvans” over
Glomeruli preparation and measurementsa period of three months or more. The injection of the
anti-Fx1A antiserum then causes an inflammatory pro- Isolation and incubation of glomeruli. Glomeruli were
isolated immediately after kidney removal by differentialcess that is localized in the rat glomeruli, the PHN [12].
Experimental procedures. (1) Group A. To assure the sieving techniques from kidney cortex, and washed three
times to remove blood cells. The procedure for glomeru-effects of PHN on proteinuria, on glomerular prostanoid
synthesis, and on COX-1 and COX-2 protein expression, lar isolation has been described in detail elsewhere [14].
Briefly, glomeruli were centrifuged three times in physio-12 rats were subjected to our study without induction of
PHN. These control rats were injected intravenously logical buffer (5 min, 500 3 g). The isolated glomeruli
were incubated for one hour in plastic tubes containingwith equivalent amounts of NaCl solution (0.9%) instead
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Fig. 1. Six hours after the induction of pas-
sive Heymann (PHN) nephritis, 10 animals
were sacrificed for morphological examina-
tion of their kidneys. By transmission electron
microscopy, electron dense “humps” localized
next to the basal membrane in glomeruli can
be seen as a marker of early onset of PHN.
2 ml of Krebs–Ringer bicarbonate buffer, pH 7.4, at 378C boxane A2 (TxA2), and 6-keto-PGF1a was determined as
stable degradation product of PGI2 (prostacyclin).after the addition of arachidonic acid at a concentration
of 50 mmol as substrate for the COXs. To stop the COX
Western blottingreaction, the probes were centrifuged in tubes at 1000 3 g
Cell lysates of isolated rat glomeruli were prepared asfor 10 minutes at 48C. The prostanoid levels in the super-
described earlier in this article. Equal amounts of cellnatant, which reflected the glomerular prostanoid pro-
protein (30 mg) were subjected to sodium dodecyl sul-duction, were determined as well as the pellet concen-
fate-polyacrylamide gel electrophoresis (SDS-PAGE)trations of prostanoids for a control. Therefore, the
and dissolved completely by electrophoresis using pro-supernatant was collected and frozen until prostanoid
tein size standards. After protein transfer to nitrocellu-determination was performed using radioimmunoassay
lose membranes in a semi-dry chamber (4 hr, 30 mA),(RIA) [15]. The glomeruli were solubilized after the
Western blot analysis was undertaken using commer-addition of lysis buffer [Tris 50 mm, EDTA 10 mm, Triton
cially available antisera: for COX-1 the monoclonal anti-X 100 1%, phenylmethylsulfonyl fluoride (PMSF) 1 mm,
body, PG 19 at 1:500, and COX-2 a polyclonal antibody,benzamidin 1 mg/ml, pH 7.2] with an ultraturax sonica-
PG 26 at 1:1000 (both specific antibodies from Oxfordtor. The glomerular protein content was determined ac-
Biochemical, Inc., Oxford, MI, USA). Protein bands were
cording to the method of Bradford [16]. Solubilized glo-
visualized using horseradish peroxidase-linked secondary
merular samples were frozen at 2208C for determination antibodies and enhanced chemiluminescence. Films
of prostanoid content and COX protein expression. were exposed to chemiluminescence approximately 30
Radioimmunoassay. Prostanoids were determined by minutes before development.
direct RIA of the supernatants without prior extraction
or chromatographic separation. The supernatant pros-
RESULTStanoids thereby reflected the amount of glomerular pros-
taglandins that were produced by viable glomeruli during Effect of flosulide on proteinuria in passive
Heymann nephritisone hour of incubation in physiological buffer with suffi-
cient substrate of 50 mmol arachidonic acid. Control mea- Untreated animals with PHN exhibited a significant
surements after 15 and 30 minutes showed no detectable proteinuria of 71 6 8 mg/24 hr (group B), whereas the
level of prostanoids. Obviously the glomerular prostan- controls (group A) showed a physiological proteinuria
oid production needed a time course of 60 minutes. Pros- of 2.0 6 0.3 mg/24 hr (Fig. 1). PHN did not reduce total
tanoid determinations performed in the solubilized glo- serum protein or serum albumin during the four weeks
merular probes represented the intracellular levels of TxB2 of the study (data not shown).
and 6-keto-PGF1a. The assay procedures, sensitivity, and Treatment with flosulide significantly reduced the pro-
specificity of the antisera used are described elsewhere teinuria in rats with PHN. The animals receiving the
lower dose (group C) showed a reduced proteinuria of[15]. TxB2 was measured as stable metabolite of throm-
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Table 1. Endogenous creatinine clearance in rats in this study
Time of determination Group A Group B Group C Group D
Day 28 ml/min 0.8660.2 0.82 60.3 0.6 6 0.1a 0.660.2a
Data are 6 sd, N 5 12.
a P , 0.01 vs. group A
observed a significant reduction of urine excretion (P ,
0.01) of the prostaglandin metabolites TxB2 and 6-keto-Fig. 2. Proteinuria in the four different study groups. Group A, study
controls; group B, rats with PHN; group C, rats with PHN and 3 mg PGF1a (Table 2).
flosulide/kg body wt/day; group D, rats with PHN and 9 mg flosulide/ During treatment with flosulide (3 mg/kg body wt/day,
kg body wt/day. *P , 0.01 vs. group B. Data are mean 6 sd of N 5
group C), the glomerular prostaglandins in the superna-12 animals per group.
tant were also significantly elevated (P , 0.01). Pellet
prostaglandin concentrations were also elevated, but this
alteration did not reach significance. On 3 mg flosulide,
26.1 6 5.8 mg/24 hr as compared with group B, which the urine excretion of prostaglandins was significantly
showed a proteinuria of 71 6 8 mg/24 hr (P , 0.05). decreased (P , 0.01).
Proteinuria in rats with PHN receiving higher-dose flo- During treatment with high-dose flosulide (group D),
sulide (group D) was also significantly reduced to 35.5 6 there was no elevation in glomerular prostanoid produc-
12.9 mg/24 hr as compared with group B animals (P , tion, and pellet concentrations of prostanoids were re-
0.05; Fig. 2). Serum protein was unchanged. Flosulide duced significantly. TxB2 was as low as 1300 6 290 pg/ml,
was able to induce a reduction of proteinuria in rats with and 6 keto-PGF1a was reduced to 1040 6 180 pg/ml (P ,
PHN at both dosages tested in our study. 0.05). The reduction of urine excretion was also ob-
served after administration of 9 mg flosulide (P , 0.01).
Endogenous creatinine clearance in rats with passive The results showed that glomerular prostaglandins in
Heymann nephritis after treatment with flosulide the supernatant were significantly elevated in PHN and
The endogenous creatinine clearance (ECCr) was used remained high after treatment with low-dose flosulide.
as a parameter of renal function. Untreated rats with High-dose flosulide therapy induced a reduction in glo-
PHN (group B) showed no significant decrease in ECCr merular prostanoid production and a significantly re-
as compared with controls. During flosulide treatment, duced prostanoid content in the pellet. Summarizing the
there was a decrease of ECCr from 0.86 6 0.2 ml/min to data, it is suggested that only high-dose COX-2 inhibition
0.6 6 0.1/min in group C and 0.6 ml 6 0.2/min in group with flosulide alters glomerular prostanoid production,
D (P , 0.01; Table 1). These results suggest a small but whereas low-dose flosulide does not change glomerular
significant nephrotoxic effect of flosulide at both dosages prostanoid production.
given in the study.
Expression of COX-1 protein
Effect of flosulide on glomerular prostaglandin The protein band of the constitutive COX, COX-1,
production in rats with passive Heymann nephritis was detected in the glomerular protein samples with a
Under the addition of arachidonic acid to glomeruli, specific monoclonal antibody as a 70 kDa band (Figs. 4
the glomerular prostanoid production was measured and 5). COX-1 expression did not quantitatively differ
after one hour of incubation in physiological buffer. In between the controls and untreated rats. The COX-1
comparative determinations of prostaglandins in the rat protein expression did not change after low-dose therapy
serum (results not shown here), no change was found in with flosulide (3 mg flosulide/kg body wt/day), while
the values associated with PHN or after therapy with the high-dose therapy (9 mg flosulide/kg body wt/day)
the COX-2 inhibitor, flosulide. This indicates that the suppressed COX-1 protein expression completely.
values determined in our study truly reflect the glomeru- The protein bands were directly compared with each
lar in vivo production of prostaglandins and that blood other. Because the amount of protein was according to
contaminations were negligible. an “all or nothing” rule, which meant that either 100%
In animals with PHN without treatment (group B), or almost no protein was detectable, the quantitation by
the glomerular TxB2 levels and the 6-keto-PGF1a levels a luminescence integral determining method was not
were significantly increased in the supernatant (P , 0.05) necessary.
as compared with the healthy controls (group A; Fig. 3).
Expression of COX-2 proteinProstanoid concentrations in the glomerular pellet were
elevated without reaching significance. In contrast to the The specific protein of the inducible COX, COX-2,
was detected in the glomerular protein lysates as a 71elevation of the glomerular prostanoid production, we
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Fig. 3. Determination of the stable metabolites of the COX-dependent prostaglandins thromboxane A (TxB2) and prostacyclin (6-keto-PGF1a)
by means of RIAs. Isolated glomeruli were incubated in Krebs-Henselein buffer (378C, pH 7.2) for 60 minutes after the addition of sufficient
substrate (50 mmol arachidonic acid) to measure renal prostanoid production. After termination of the cyclooxygenase reaction by centrifugation
(1,000 * g, 10 min), samples of supernatant were collected, and glomeruli were solubilized. In both fractions, TxB2 and 6-keto-PGF1a were determined
(X 6 sem; N 5 12). Significance was calculated according to the Mann-Whitney U-test in comparison with group B: *P , 0.05, **P , 0.01.
Table 2. Effects of flosulide on renal prostanoid production and urine excretion of prostanoids
Renal prostanoid production Urine excretion of prostanoids
pg/mg glomerular protein ng/g creatinine excretion
TxB2 6-keto-PGF1a TxB2 6-keto-PGF1a
Group A 30736355 17026161 308636 246622
Group B 525561041 27246770 177618 137.5611
P ,0.05 ,0.05 ,0.01 ,0.01
Group C 597561465 30286573 8268.2 86631
P ,0.01 ,0.01 ,0.01 ,0.01
Group D 36866499 26336714 83611 7964.7
P NS NS ,0.01 ,0.01
Concentrations were determined by radioimmunoassay. Data are shown as 6 sd, N 5 12. P values are compared with group A. NS is not significant.
kDa band using a specific antiserum (Fig. 3). Comparable of the films to chemiluminescence (data not shown) that
reflected the basal expression of COX-2. In the glomeruliresults for vascular smooth muscle cells of the rat are
in literature [17]. Furthermore, the amount of detected of group B (12 rats with PHN; Fig. 3), a strong induction
of COX-2 during PHN was found. The markedly ele-protein could be compared with the constitutively ex-
pressed COX-1 isoform. vated protein expression compared with the controls was
clearly evident on day 14 of the study.In the glomeruli of group A (12 control animals), only
a narrow band was demonstrated after a long exposure Cyclooxygenase 2 protein expression in group C rats
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Fig. 4. Western blots showing the specific detection of COX-2 as a 71 kD protein band in solubilized rat glomeruli. All lanes contain a total of
30 mg protein of the glomerular probes that were solubilized according to the experimental protocol described in the Methods section. Probes of
the corresponding group (N 5 12) showed comparable results. B0 is a protein sample of group B (rats with PHN) on day 14; D1 and D2, protein
samples of group D (rats with PHN, 9 mg flosulide/kg body wt/day) on day 28; B1 and B2, protein samples of group B (rats with PHN, no treatment)
on day 28; C1 and C2, protein samples of group C (rats with PHN, 3 mg flosulide/kg body wt/day) on day 28; A1 and A2 are protein samples of
group A (controls) on day 28.
Fig. 5. Western blots showing the specific detection of COX-1 as a 70 kD protein band in solubilized rat glomeruli. All lanes contain a total of
30 mg protein of the glomerular probes that were solubilized according to the experimental protocol described in the Methods section. Probes of
the corresponding group (N 5 12) showed comparable results. A1 and A2 are protein samples of group A (controls) on day 28. B1 and B2 are
protein samples of group B (rats with PHN, no treatment) on day 28. C1 and C2 are protein samples of group C (rats with PHN, 3 mg flosulide/
kg body wt/day) on day 28. D1 and D2, protein samples of group D (rats with PHN, 9 mg flosulide/kg body wt/day) on day 28.
(low-dose flosulide therapy for PHN) was comparable named flosulide, in PHN. This investigation was con-
to the protein expression in untreated animals (group B). ducted in vivo to test if the selective COX-2 inhibitor
In contrast, COX-2 protein expression was markedly sup- (flosulide) affected renal function, COXs, or renal pros-
pressed in rats treated with high-dose flosulide (group D). taglandin production. PHN in the rat was used as an
Apparently, an up-regulation of COX-2, the inducible animal model. The renal histology was investigated once
isoform of COXs, occurred in conjunction with PHN, by the use of electron microscopy to prove the early
compared with an only slightly pronounced basal expres- onset of PHN after injection of the anti-FxA1 antibody
sion. At the higher dose (9 mg/kg body wt/day), the to the animals. Structural changes in rat kidney after
flosulide-induced inhibition of the enzyme caused a re- therapy with a highly selective COX-2 inhibitor might
duction in the protein expression of COX-2, whereas correlate with biochemical and physiological findings,
protein expression on 3 mg flosulide/kg body wt/day re- but this was not investigated further.
mained approximately the same. In the kidney, prostanoids are produced mainly in the
medulla, in the ascending loop, and in the cortex. Renal
COXs participate in the regulation of renal blood flow,DISCUSSION
sodium and water reabsorption, and the release of renin.Little information exists on the pharmacological ac-
All of these functions are mainly regulated by COX-1,tion of COX-2–selective inhibitors in the kidney [18].
but the release of renin may also be regulated by COX-2The availability of a COX-2 selective inhibitor encour-
[19]. COX-2 has been detected in the kidney as wellaged us to examine its potential therapeutic effect on
[20], and its activation probably represents an importantinflammatory processes in the kidney. The aim of this
compensatory mechanism for maintaining sufficientstudy was to investigate the therapeutic action of 6-(2, 4)
blood flow in the kidney during pathogenic processesdifluorophenoxy-5-methyl - sulfonylamino-1 - indanone
(CGP 28,238), a phenoxyindane-methane-esulfonamide [7]. PHN represents this type of critical inflammatory
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situation in the kidney, and is characterized by the rapid In our study, all urinary prostaglandin levels were very
low, although the measured glomerular prostaglandinsproduction of local prostaglandins as well as other fea-
tures. This takes place directly following injection of the reached quite high levels. This was already the case in
the study of Heise et al, which concerned flosulide treat-irritating antibody directed against the tubular antigen
Fx1A [11, 12]. ment of rats with PHN until day 14 [25]. As Ciabattoni
and Pugliese reported [8], the urinary excretion of pros-Previous studies showed that all mice with a knockout
of all COX-2 isoenzymes develop renal dysplasia and taglandins reflects the situation of the whole kidney pro-
duction, including tubular cells, mesangial cells, and glo-half of them develop cardiac fibrosis [21]. The lack of
COX-2 did not in any way affect the inflammatory capac- merular cells. Our data suggest that the urinary excretion
of prostaglandins does not completely reflect the overallity of their immune systems. Although not all reasons
for those circumstances are yet fully understood, it has prostaglandin production in PHN, which is obviously
focused on the glomeruli. This coincides with the factbecome clear that COX-2 is essential for physiological
functions and that a total inhibition of COX-2 action that the PHN represents an inflammatory disease of the
glomeruli in first line with a severe glomerular injury.might not be favorable toward continued health.
Investigations on the detailed function of COX-1 and Urinary prostaglandins were shown to be unsuitable to
study the effect of a COX-2 inhibitor on the course ofCOX-2 in the kidney are not yet complete. COX-2 has
been found to be up-regulated in inflammatory condi- prostaglandin production in PHN.
In contrast, the glomerular prostaglandins, which aretions. Therefore, the therapeutic use of COX-2 inhibitors
as specific anti-inflammatory agents was considered [22]. highly elevated in PHN [24], remained high during ther-
apy with low-dose flosulide. Enhanced prostaglandin syn-Investigations in the stomach have shown that COX-2
inhibitors exhibit minor toxicity while maintaining their thesis of the glomeruli was associated with elevated
COX-2 protein expression, but not with an elevation ofanti-inflammatory action [23]. Comparable results have
not been previously found in the kidney [6]. Therefore, COX-1 protein expression. COX-1 protein expression re-
mained unchanged and was easily detectable in both theit seemed plausible to inhibit COX-2 as a modulator of
inflammation, while the supply of prostanoid precursors controls and the animals suffering from PHN and not re-
ceiving therapy. Apparently, an inflammatory stimulus didby COX-1 could remain undisturbed.
In our study, rats with PHN developed proteinuria not change the expression of the constitutive isoenzyme.
The increase in glomerular prostaglandins in conjunctionand elevated glomerular prostaglandin synthesis, which
is concordant with previous studies [24]. Despite the with PHN thus appeared to be COX-2 dependent.
Therapy with flosulide induced a significant reductionincreasing evidence for enhanced intrarenal production
of eicosanoids in a number of experimental as well as in proteinuria. This effect occurred in a dose-independent
manner in the two dosage groups. These results suggestedclinical forms of glomerulonephritis, the cause and cellu-
lar source of these products remain controversial. These that selective COX-2 inhibitors possess an anti-inflamma-
tory, immunomodulatory effect in inflammatory processescells were either infiltrating blood elements such as leu-
kocytes, monocytes, and platelets, recruited and acti- of the kidney. The remaining prostanoid production is
generally believed to be essential for the maintenance ofvated to synthesize eicosanoids at the site of glomerular
injury, or were glomerular epithelial and mesangial cells. glomerular filtration rate in critical inflammatory condi-
tions of the kidney [7]. In this study, a nonspecific, nephro-The latter intrinsic glomerular cells could possibly be
activated by a number of inflammatory factors. Alter- toxic effect of flosulide had to be excluded as a possible
explanation for the antiproteinuric action of the drug. Weations in anionic structures of the glomerulus as well as
increased renal eicosanoid synthesis have been described evaluated renal function in all therapy groups in terms of
ECCr and compared them with each other. A small thoughin glomerular disease. Unlike other mediators, eicosa-
noids formed within the kidney are not stored following significant reduction in ECCr to 0.6 ml/min compared with
0.86 ml/min in controls was shown on flosulide. Thus, itsynthesis, but are either locally metabolized or removed
from the kidney in the lymphatic and venous drainage can be assumed that a certain nephrotoxicity existed in
both groups. After all, the reduced clearance performanceor excreted into the urine [8].
In parallel experiments we measured the glomerular of the kidney alone is not enough to explain the differences
in protein expression and prostaglandin production foundproduction of the stable prostaglandin metabolites TxB2
and PGE2 (reflecting TxA2 and prostacyclin as active between the two dosage groups, but may support the
antiproteinuric action.prostaglandins) in two compartments of the kidney, in
the protein lysates of the glomeruli, as well as in the In contrast to its antiproteinuric action, the effect of
flosulide on glomerular prostaglandin production and onsupernatant of the incubated glomeruli after the removal
of blood cells by careful washing of the glomeruli. Fur- the protein expression of COX-2 was dependent on the
dose administered. Low-dose flosulide therapy did not leadthermore, we measured the urinary excretion of the pros-
taglandins in all four therapeutic rat groups. to any major changes in renal prostaglandin production
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or in COX-2 protein expression, whereas COX-1 protein compared with indomethacin and diclofenac was approx-
expression remained unchanged. imately equal with regards to COX-2 in rat mesangial
A marked effect was shown with 9 mg flosulide/kg cells. Summarizing, Klein et al showed that for flosulide,
body wt/day, as there was a significant reduction in pros- the ratio of IC50COX-2/IC50COX-1 amounts to 5000, demon-
taglandin production, although the TxA2 levels were strating a high selectivity of this drug for COX-2.
more affected than the prostacyclin content. In addition In conclusion, we observed that when low-dose flosul-
to this, suppression of COX-2 protein expression was ide was used, the proteinuria in PHN was reduced, but
also observed on high-dose flosulide therapy. The sup- the elevated prostaglandin levels remained unaffected.
pression of COX-1 protein expression after high-dose COX-1 and COX-2 protein expression remained un-
flosulide administration indicates that the drug’s action changed. With high-dose flosulide, proteinuria was still
is nonselective within this dose range. This observation reduced, but renal prostaglandin levels were also re-
was also made by other authors [9, 20, 26]. The drop duced. COX-1 and COX-2 protein expression was highly
in prostaglandins on high-dose flosulide therapy might suppressed.
therefore be induced by an additional impairment of There is actually only one comparable study on COX-2
COX-1. inhibitors in the kidney [28]. Hirose et al showed that
When studied by Western blotting, both COX-1 and in the anti–Thy-1 glomerulonephritis, the COX-2 protein
COX-2 protein were not detectable when animals were was induced on days 4 and 10 during but not in the
treated with high-dose flosulide. Possible explanations glomeruli of control rats. COX-2 was localized exclu-
of this finding remain speculative, because detailed ex- sively in glomerular epithelial cells, as shown in our study
aminations of possible transcriptional or translational in PHN. In contrast to our results, the COX-1 protein
mechanisms are missing. There are only few studies on in Hirose’s study was not or only faintly detected in rat
the molecular signal pathway of the COX-2 expression. control glomeruli, which could be due to the localization
One recent publication reports that TLCK, a serine pro- (shown by immunofluorescence) along glomerular capil-
tease inhibitor (Nalpha-P-tosyl-l-lysine chloromethyl lary walls but not directly in the glomeruli. That study
ketone, 100 mmol/liter) and MG 132, a proteasome com- actually shows no comparable investigations on the ef-
plex (26S) inhibitor (10 mmol/liter), inhibited interleu-
fect of COX-2 inhibitors on glomerular prostaglandin
kin-1b–induced COX-2 enzyme activity (PGE2 forma- production.tion) and COX-2 gene expression at the level of mRNA
Although the investigations concerning the detailedand protein in rat mesangial cells [27].
function of COX-1 and COX-2 in kidney are not yetBecause the expression of both COX enzymes 1 and
finished, our results from experiments in rats clearly indi-2 are blocked under high-dose flosulide, it appears to be
cate that the use of a COX-2–selective inhibitor such aslikely that high-dose flosulide leads to an inhibition of
flosulide in a low-dosage range represents an interestingprotein synthesis of COX-1 and COX-2. By which mech-
immunomodulatory therapeutic concept. Its benefit isanisms this occurs remains unclear. It is possible that nega-
probably based on the fact that the low-dose applicationtive feedback mechanisms play a role, but it is also likely
of flosulide leaves the supply of prostanoid precursors inthat high-dose flosulide might be toxic for renal cells and
the glomeruli untouched. This important compensatorymight affect renal cell viability in general. This hypothesis
mechanism of the kidney seems to be essential for theagrees with the fact that flosulide has been removed from
maintenance of renal perfusion in critical inflammatorythe market because of its nephrotoxicity [9].
situations of the kidney. COX-2 inhibitors are also dis-The fact that the prostaglandins remained high on
cussed as anticancer agents as well as in preventing pre-low-dose flosulide could suggest that COX-1 fulfills the
mature labor, and perhaps even as a factor retarding thefunction of maintaining the synthesis of prostaglandin
progression of Alzheimer’s disease [18]. In any case,precursors while COX-2 is inhibited. On the other hand,
whether or not the therapeutic application of COX-2it has to be considered whether flosulide inhibition of
inhibitors in patients with glomerulonephritis over aCOX-2 is complete. The selectivity of flosulide has been
longer period of time might be beneficial remains anshown by Klein et al [20], who studied COX-2 induction
interesting subject for further investigation [13].in rat mesangial cells by immunoblot analysis. In parallel
experiments, human platelets, known to host only
COX-1, were taken to study inhibitory effects on the ACKNOWLEDGMENTS
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